Evaluation of an Antibiotic Treatment With 14 Days of Intravenous Tobramycin Versus the Same Antibiotic Associated With 5 Days of Intravenous Tobramycin Followed by Tobramycin Aerosol for 9 Days in Cystic Fibrosis.

Trial Profile

Evaluation of an Antibiotic Treatment With 14 Days of Intravenous Tobramycin Versus the Same Antibiotic Associated With 5 Days of Intravenous Tobramycin Followed by Tobramycin Aerosol for 9 Days in Cystic Fibrosis.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Tobramycin (Primary) ; Tobramycin (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms TOBRAMUC
  • Most Recent Events

    • 16 Feb 2018 Planned End Date changed from 1 Dec 2019 to 1 Feb 2021.
    • 16 Feb 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2021.
    • 21 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top